Sworczak Krzysztof, Zaczek Anna, Babinska Anna, Lisowska Urszula, Bielawski Krzysztof P, Falkiewicz Bogdan
Department of Internal Medicine, Endocrinology and Hemostasis, Faculty of Medicine, Medical University of Gdansk, 80-742 Gdansk, Poland.
Oncol Rep. 2002 Nov-Dec;9(6):1373-8.
ErbB-1, -2, -3 and -4 proteins are growth factor receptors, encoded by the family of respective erbB protooncogenes. These receptor-encoding proto-oncogenes frequently undergo amplification, and less frequently, a deletion, in several human neoplasms. The role of the ErbB family in human endocrine neoplasms, including pheochromocytoma (PHEO), was not extensively tested and not previously established. The expression/overexpression of erbB oncogenes in pheochromocytoma tissue was determined only in a few cases, and to the best of our knowledge, their mutations (amplification or deletion) were not examined in any series of PHEO cases. We, therefore, used a double differential polymerase chain reaction (ddPCR) for determination of the amplification/deletion profiles of erbB-1, -2, -3 and -4 genes in formalin-fixed, paraffin embedded (FFPE) specimens of human PHEOs. We examined the average gene copy number (AGCN) of the genes in 36 samples of pheochromocytomas (2 extra-adrenal and 34 adrenal tumors). We found the mean AGCNs of the oncogenes equal 1.18 for erbB-1 [amplification was found in 11/35 cases (31%) and deletion in 6/35 cases (17%)], 2.00 for erbB-2 [amplification was found in 8/34 cases (24%), no deletion was found], 1.36 for erbB-3 [amplification was found in 4/36 cases (11%) and deletion in 1/36 cases (3%)], and 1.22 for erbB-4 [amplification was found in 5/30 cases (17%) and deletion in 1/30 cases (3%)]. A mutation(s) of any erbB oncogene was found in 25/36 (69%) samples tested. Some abnormalities of the erbB oncogenes showed interesting correlations with one another and with clinical features of the tumors. The frequent occurrence of amplifications and deletions of the erbB oncogenes in human pheochromocytoma implies the importance of the gene family in the development of these tumors.
ErbB-1、-2、-3和-4蛋白是生长因子受体,由各自的erbB原癌基因家族编码。这些编码受体的原癌基因在几种人类肿瘤中经常发生扩增,较少发生缺失。ErbB家族在包括嗜铬细胞瘤(PHEO)在内的人类内分泌肿瘤中的作用尚未得到广泛测试,此前也未确定。仅在少数病例中测定了嗜铬细胞瘤组织中erbB原癌基因的表达/过表达,据我们所知,在任何一系列PHEO病例中均未检测到它们的突变(扩增或缺失)。因此,我们使用双重差异聚合酶链反应(ddPCR)来测定人PHEO福尔马林固定、石蜡包埋(FFPE)标本中erbB-1、-2、-3和-4基因的扩增/缺失情况。我们检测了36例嗜铬细胞瘤样本(2例肾上腺外肿瘤和34例肾上腺肿瘤)中这些基因的平均基因拷贝数(AGCN)。我们发现,erbB-1原癌基因的平均AGCN为1.18 [11/35例(31%)发现扩增,6/35例(17%)发现缺失],erbB-2为2.00 [8/34例(24%)发现扩增,未发现缺失],erbB-3为1.36 [4/36例(11%)发现扩增,1/36例(3%)发现缺失],erbB-4为1.22 [5/30例(17%)发现扩增,1/30例(3%)发现缺失]。在检测的25/36(69%)样本中发现了任何erbB原癌基因的突变。erbB原癌基因的一些异常相互之间以及与肿瘤的临床特征显示出有趣的相关性。人类嗜铬细胞瘤中erbB原癌基因频繁发生扩增和缺失,这意味着该基因家族在这些肿瘤的发生发展中具有重要作用。